摘要
癌症的特征在于高死亡率和低固化性。 最近的研究表明，肿瘤抗性的机制不仅涉及肿瘤细胞的内源性变化，还涉及肿瘤微环境（TME），它为癌细胞的生长，侵袭和转移提供了必要的条件，类似于Stephen Paget的对“种子和土壤”的假设。因此，TME是通过纳米颗粒进行癌症治疗的重要目标，纳米颗粒可以携带针对不同类型或阶段的肿瘤的不同种类的药物。 纳米疗法的关键步骤是实现精确的主动或被动靶向，以在肿瘤细胞中精确地触发药物，具有较低的毒性和较少的副作用。 随着对肿瘤微环境的深入理解和纳米材料工业的快速发展，纳米疗法的机制可以根据特定的TME特征个体化，包括低pH，癌症相关成纤维细胞（CAF）和增加的金属蛋白酶表达。 然而，TME的一些异常特征限制了药物的致死浓度到达所有肿瘤细胞，并且肿瘤的特征在许多方面变化，导致纳米疗法的临床应用的巨大挑战。 在这篇综述中，我们讨论了肿瘤微环境在肿瘤发生和发展中的重要作用，以及改善肿瘤微环境靶向纳米粒子的治疗效果所需的措施以及减少对正常组织损伤的方法。
关键词: 肿瘤微环境，纳米疗法，纳米粒子，靶向治疗，纳米医学，纳米技术。
图形摘要
[1]
Bhatt, A.P.; Redinbo, M.R.; Bultman, S.J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin., 2017, 67(4), 326-344.
[2]
Wang, L.; Huo, M.; Chen, Y.; Shi, J. Tumor microenvironment-enabled nanotherapy; Adv. Health Mater, 2017.
[http://dx.doi.org/10.1002/adhm.201701156.]
[http://dx.doi.org/10.1002/adhm.201701156.]
[3]
Tian, J.; Min, Y.; Rodgers, Z.; Au, K.M.; Hagan, C.T.; Zhang, M.; Roche, K.; Yang, F.; Wagner, K.; Wang, A.Z. Co-delivery of paclitaxel and cisplatin with biocompatible PLGA-PEG nanoparticles enhances chemoradiotherapy in non-small cell lung cancer models. J. Mater. Chem. B Mater. Biol. Med., 2017, 5, 6049-6057.
[4]
Guo, G.; Tortorella, M.; Zhang, B.; Wang, Y. Disassembly of micelle-like polyethylenimine nanocomplexes for siRNA delivery: High transfection efficiency and reduced toxicity achieved by simple reducible lipid modification. J. Colloid Interface Sci., 2017, 504, 633-644.
[5]
Tian, L.; Bae, Y.H. Cancer nanomedicines targeting tumor extracellular pH. Colloids Surf. B Biointerfaces, 2012, 99, 116-126.
[6]
Gao, Z.; Zhang, L.; Sun, Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release, 2012, 162, 45-55.
[7]
Al-Yasiri, A.Y.; Khoobchandani, M.; Cutler, C.S.; Watkinson, L.; Carmack, T.; Smith, C.J.; Kuchuk, M.; Loyalka, S.K.; Lugão, A.B.; Katti, K.V. Mangiferin functionalized radioactive gold nanoparticles (MGF-(198)AuNPs) in prostate tumor therapy: Green nanotechnology for production, in vivo tumor retention and evaluation of therapeutic efficacy. Dalton Trans., 2017, 46(42), 1456-1471.
[8]
Roy, A.; Li, S.D. Modifying the tumor microenvironment using nanoparticle therapeutics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2016, 8(6), 891-908.
[9]
Witz, I.P. The tumor microenvironment: the making of a paradigm. Cancer Microenviron., 2009, 2(Suppl. 1), 9-17.
[10]
Muntimadugu, E.; Kommineni, N.; Khan, W. Exploring the potential of nanotherapeutics in targeting tumor microenvironment for cancer therapy. Pharmacol. Res., 2017, (126), 109-122.
[11]
Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 2007, 9, 654-659.
[12]
Zou, W.; Chen, L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol., 2008, 8, 467-477.
[13]
Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol., 2007, 7, 41-51.
[14]
Pahl, J.; Cerwenka, A. Tricking the balance: NK cells in anti-cancer immunity. Immunobiology, 2017, 222, 11-20.
[15]
Spaks, A. Role of CXC group chemokines in lung cancer development and progression. J. Thorac. Dis., 2017, 9, S164-S171.
[16]
Persano, L.; Rampazzo, E.; Basso, G.; Viola, G. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem. Pharmacol., 2013, 85, 612-622.
[17]
Xin, Y.; Huang, M.; Guo, W.W.; Huang, Q.; Zhang, L.Z.; Jiang, G. Nano-based delivery of RNAi in cancer therapy. Mol. Cancer, 2017, 16, 134.
[18]
Kang, B.; Kukreja, A.; Song, D.; Huh, Y.M.; Haam, S. Strategies for using nanoprobes to perceive and treat cancer activity: A review. J. Biol. Eng., 2017, 11, 13.
[19]
Ji, T.; Zhao, Y.; Ding, Y.; Nie, G. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. Adv. Mater.Weinheim, 2013, 25, 3508-3525.
[20]
Upreti, M.; Jyoti, A.; Sethi, P. Tumor microenvironment and nanotherapeutics. Transl. Cancer Res., 2013, 2, 309-319.
[21]
Huang, S.; Shao, K.; Liu, Y.; Kuang, Y.; Li, J.; An, S.; Guo, Y.; Ma, H.; Jiang, C. Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis. ACS Nano, 2013, 7, 2860-2871.
[22]
Luciano, R.; Battafarano, G.; Saracino, R.; Rossi, M.; Perrotta, A.; Manco, M.; Muraca, M.; Del Fattore, A. New perspectives in glioblastoma: nanoparticles-based approaches. Curr. Cancer Drug Targets, 2017, 17, 203-220.
[23]
Park, J.; Wrzesinski, S.H.; Stern, E.; Look, M.; Criscione, J.; Ragheb, R.; Jay, S.M.; Demento, S.L.; Agawu, A.; Licona, L.P.; Ferrandino, A.F.; Gonzalez, D.; Habermann, A.; Flavell, R.A.; Fahmy, T.M. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater., 2012, 11, 895-905.
[24]
Feczkó, T.; Fodor-Kardos, A.; Sivakumaran, M.; Haque, S.Q.T. In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles. Nanomedicine (Lond), 2016, 11, 2029-2034.
[25]
Shvedova, A.A.; Tkach, A.V.; Kisin, E.R.; Khaliullin, T.; Stanley, S.; Gutkin, D.W.; Star, A.; Chen, Y.; Shurin, G.V.; Kagan, V.E.; Shurin, M.R. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small, 2013, 9, 1691-1695.
[26]
Nakamura, Y.; Mochida, A.; Choyke, P.L.; Kobayashi, H. Nanodrug delivery: Is the enhanced permeability and retention effect sufficient for curing cancer. Bioconjug. Chem., 2016, 27, 2225-2238.
[27]
Adiseshaiah, P.P.; Hall, J.B.; McNeil, S.E. Nanomaterial standards for efficacy and toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2010, 2, 99-112.
[28]
Lee, K.Y.; Lee, G.Y.; Lane, L.A.; Li, B.; Wang, J.; Lu, Q.; Wang, Y.; Nie, S. Functionalized, long-circulating, and ultrasmall gold nanocarriers for overcoming the barriers of low nanoparticle delivery efficiency and poor tumor penetration. Bioconjug. Chem., 2017, 28, 244-252.
[29]
Stylianopoulos, T.; Jain, R.K. Design considerations for nanotherapeutics in oncology. Nanomedicine , 2015, 11, 1893-1907.
[30]
Wong, C.; Stylianopoulos, T.; Cui, J.; Martin, J.; Chauhan, V.P.; Jiang, W.; Popovic, Z.; Jain, R.K.; Bawendi, M.G.; Fukumura, D. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. USA, 2011, 108, 2426-2431.
[31]
Carter, T.; Mulholland, P.; Chester, K. Antibody-targeted nanoparticles for cancer treatment. Immunotherapy, 2016, 8, 941-958.
[32]
Akhtar, M.J.; Ahamed, M.; Alhadlaq, H.A.; Alrokayan, S.A.; Kumar, S. Targeted anticancer therapy: Overexpressed receptors and nanotechnology. Clin. Chim. Acta, 2014, 436, 78-92.
[33]
Kaur, S.; Prasad, C.; Balakrishnan, B.; Banerjee, R. Trigger responsive polymeric nanocarriers for cancer therapy. Biomater. Sci., 2015, 3, 955-987.
[34]
Du, J.Z.; Mao, C.Q.; Yuan, Y.Y.; Yang, X.Z.; Wang, J. Tumor extracellular acidity-activated nanoparticles as drug delivery systems for enhanced cancer therapy. Biotechnol. Adv., 2014, 32, 789-803.
[35]
Zhu, J.; Liao, L.; Bian, X.; Kong, J.; Yang, P.; Liu, B. pH-controlled delivery of doxorubicin to cancer cells, based on small mesoporous carbon nanospheres. Small, 2012, 8, 2715-2720.
[36]
Qian, W.Y.; Sun, D.M.; Zhu, R.R.; Du, X.L.; Liu, H.; Wang, S.L. pH-sensitive strontium carbonate nanoparticles as new anticancer vehicles for controlled etoposide release. Int. J. Nanomedicine, 2012, 7, 5781-5792.
[37]
Kanamala, M.; Wilson, W.R.; Yang, M.; Palmer, B.D.; Wu, Z. Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review. Biomaterials, 2016, 85, 152-167.
[38]
Corbet, C.; Feron, O. Tumour acidosis: From the passenger to the driver’s seat. Nat. Rev. Cancer, 2017, 17(10), 577-593.
[39]
Nakazawa, M.S.; Keith, B.; Simon, M.C. Oxygen availability and metabolic adaptations. Nat. Rev. Cancer, 2016, 16(10), 663-673.
[40]
Scheuermann, T.H.; Li, Q.; Ma, H.W.; Key, J.; Zhang, L.; Chen, R.; Garcia, J.A.; Naidoo, J.; Longgood, J.; Frantz, D.E.; Tambar, U.K.; Gardner, K.H.; Bruick, R.K. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol., 2013, 9(4), 271-276.
[41]
Pourmorteza, M.; Rahman, Z.U.; Young, M. Evofosfamide, a new horizon in the treatment of pancreatic cancer. Anticancer Drugs, 2016, 27(8), 723-725.
[42]
Lohse, I.; Rasowski, J.; Cao, P.; Pintilie, M.; Do, T.; Tsao, M.S.; Hill, R.P.; Hedley, D.W. Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302. Oncotarget, 2016, 7(23), 33571-33580.
[43]
Torosean, S.; Flynn, B.; Axelsson, J.; Gunn, J.; Samkoe, K.S.; Hasan, T.; Doyley, M.M.; Pogue, B.W. Nanoparticle uptake in tumors is mediated by the interplay of vascular and collagen density with interstitial pressure. Nanomedicine , 2013, 9, 151-158.
[44]
Singh, Y.; Pawar, V.K.; Meher, J.G.; Raval, K.; Kumar, A.; Shrivastava, R.; Bhadauria, S.; Chourasia, M.K. Targeting tumor associated macrophages (TAMs) via nanocarriers. J. Control. Release, 2017, 254, 92-106.
[45]
Wang, Y.; Lin, Y.X.; Qiao, S.L.; An, H.W.; Ma, Y.; Qiao, Z.Y.; Rajapaksha, R.P.; Wang, H. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. Biomaterials, 2017, 112, 153-163.
[46]
Wang, T.; Shigdar, S.; Shamaileh, H.A.; Gantier, M.P.; Yin, W.; Xiang, D.; Wang, L.; Zhou, S.F.; Hou, Y.; Wang, P.; Zhang, W.; Pu, C.; Duan, W. Challenges and opportunities for siRNA-based cancer treatment. Cancer Lett., 2017, 387, 77-83.
[47]
Danhier, F.; Feron, O.; Préat, V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010, 148, 135-146.
[48]
Ruan, S.; He, Q.; Gao, H. Matrix metalloproteinase triggered size-shrinkable gelatin-gold fabricated nanoparticles for tumor microenvironment sensitive penetration and diagnosis of glioma. Nanoscale, 2015, 7, 9487-9496.
[49]
Pastorino, L.; Erokhina, S.; Caneva-Soumetz, F.; Ruggiero, C. Paclitaxel-containing nano-engineered polymeric capsules towards cancer therapy. J. Nanosci. Nanotechnol., 2009, 9, 6753-6759.
[50]
Yim, H.; Park, S.J.; Bae, Y.H.; Na, K. Biodegradable cationic nanoparticles loaded with an anticancer drug for deep penetration of heterogeneous tumours. Biomaterials, 2013, 34, 7674-7682.
[51]
Lee, Y.; Thompson, D.H. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2017, 9(5), e1450.
[52]
Sassaroli, E.; Li, K.C.; O’Neill, B.E. Numerical investigation of heating of a gold nanoparticle and the surrounding microenvironment by nanosecond laser pulses for nanomedicine applications. Phys. Med. Biol., 2009, 54, 5541-5560.
[53]
Cheng, R.; Meng, F.; Deng, C.; Klok, H.A.; Zhong, Z. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials, 2013, 34, 3647-3657.
[54]
Shao, Y.; Fu, J. Integrated micro/nanoengineered functional biomaterials for cell mechanics and mechanobiology: a materials perspective. Adv. Mater.Weinheim, 2014, 26, 1494-1533.
[55]
Zhu, L.; Torchilin, V.P. Stimulus-responsive nanopreparations for tumor targeting. Integr. Biol., 2013, 5, 96-107.
[56]
Spencer, D.S.; Puranik, A.S.; Peppas, N.A. Intelligent nanoparticles for advanced drug delivery in cancer treatment. Curr. Opin. Chem. Eng., 2015, 7, 84-92.
[57]
Liu, Y.; Ding, X.; Li, J.; Luo, Z.; Hu, Y.; Liu, J.; Dai, L.; Zhou, J.; Hou, C.; Cai, K. Enzyme responsive drug delivery system based on mesoporous silica nanoparticles for tumor therapy in vivo. Nanotechnology, 2015, 26, 145102.
[58]
Chen, W.H.; Luo, G.F.; Lei, Q.; Cao, F.Y.; Fan, J.X.; Qiu, W.X.; Jia, H.Z.; Hong, S.; Fang, F.; Zeng, X.; Zhuo, R.X.; Zhang, X.Z. Rational design of multifunctional magnetic mesoporous silica nanoparticle for tumor-targeted magnetic resonance imaging and precise therapy. Biomaterials, 2016, 76, 87-101.
[59]
Chen, Y.; Ye, D.; Wu, M.; Chen, H.; Zhang, L.; Shi, J.; Wang, L. Break-up of two-dimensional MnO2 nanosheets promotes ultrasensitive pH-triggered theranostics of cancer. Adv. Mater.Weinheim, 2014, 26, 7019-7026.
[60]
Krishnamurthy, S.; Vaiyapuri, R.; Zhang, L.; Chan, J.M. Lipid-coated polymeric nanoparticles for cancer drug delivery. Biomater. Sci., 2015, 3, 923-936.
[61]
Suarato, G.; Li, W.; Meng, Y. Role of pH-responsiveness in the design of chitosan-based cancer nanotherapeutics: A review.Biointerphases, 2016. 11, 04B201.
[62]
Curtis, L.T.; Frieboes, H.B. The Tumor Microenvironment as a Barrier to Cancer Nanotherapy. Adv. Exp. Med. Biol., 2016, 936, 165-190.
[63]
Jhaveri, A.; Deshpande, P.; Torchilin, V. Stimuli-sensitive nanopreparations for combination cancer therapy. J. Control. Release, 2014, 190, 352-370.
[64]
van de Ven, A.L.; Wu, M.; Lowengrub, J.; McDougall, S.R.; Chaplain, M.A.; Cristini, V.; Ferrari, M.; Frieboes, H.B. Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv., 2012, 2, 11208.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
96
10
1
2